Greater walking was associated with reduced severe fatigue at 6 and 12 months and improved quality of life at each follow-up, ...
Mosunetuzumab’s 2022 approval introduced off-the-shelf T-cell redirection in follicular lymphoma, enabling faster initiation and broader site-of-care feasibility than individualized CAR-T ...
A wife reflects on her husband’s cancer treatment, finding comfort, hope and connection in their simple ritual of sharing ...
Therapeutic resistance after endocrine therapy and CDK4/6 inhibitors remains a key unmet need in metastatic ...
A wife reflects on her husband’s cancer treatment, finding comfort, hope and connection in their simple ritual of sharing bagels before each treatment.
September is Blood Cancer Awareness Month, and recent weeks have brought major changes for people with blood cancers. In August, the FDA approved three treatments: Zenbexus (iberdomide) for relapsed ...
A genomic test led physicians to change extended endocrine therapy recommendations for 42% of people with early-stage HR-positive breast cancer. Results from the Breast Cancer Index (BCI) test led ...
Survivors and experts who have spoken with CURE share what to do before your first infusion, from saving your hair and protecting your skin to building a support team. The good news is that patients ...
FDA authorized belzutifan plus lenvatinib for advanced clear cell–component RCC following PD-1/PD-L1 inhibitor exposure, including progression during/after therapy or within six months of adjuvant ...
CAR-T therapy reprograms autologous T cells to recognize leukemia, is generally reserved for relapsed/refractory B-cell ALL, and can provide ongoing immune surveillance when cells persist. Post–CAR-T ...
After 18 years of living with multiple myeloma, Sally Kalksma has learned that getting through cancer treatment is about more ...
The omnipresence of pink during awareness campaigns can function as an involuntary cue for trauma recall, reactivating uncertainty, grief, and embodied memories tied to cancer care. Survivorship is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results